Source: iQoncept / Shutterstock
CRISPR Therapeutics (NASDAQ:CRSP) just reported results for the first quarter of 2024.
- CRISPR Therapeutics reported earnings per share of -$1.43. This was below the analyst estimate for EPS of -$1.42.
- The company reported revenue of $504,000.
- This was 98.21% worse than the analyst estimate for revenue of $28.11 million.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/crsp-stock-earnings-crispr-therapeutics-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC